Amuvatinib
- Generic Name
- Amuvatinib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C23H21N5O3S
- CAS Number
- 850879-09-3
- Unique Ingredient Identifier
- SO9S6QZB4R
- Background
Amuvatinib has been used in trials studying the treatment of Solid Tumors and Small Cell Lung Carcinoma. Amuvatinib is an oral, selective multi-targeted tyrosine kinase inhibitor that suppresses c-MET, c-RET and the mutant forms of c-KIT, PDGFR and FLT3. Amuvatinib also suppresses Rad51 protein, a critical component of double-stranded DNA repair in cancer ce...
- Indication
Amuvatinib is a selective multi-targeted tyrosine kinase inhibitor that suppresses c-MET, c-RET and the mutant forms of c-KIT, PDGFR and FLT3. Amuvatinib also suppresses Rad51 protein, a critical component of double-stranded DNA repair in cancer cells.
- Associated Conditions
- -
- Associated Therapies
- -
A Phase 2, Open-Label Study of Amuvatinib in Combination With Platinum-Etoposide Chemotherapy in Small Cell Lung Cancer
- First Posted Date
- 2011-05-20
- Last Posted Date
- 2024-08-02
- Lead Sponsor
- Astex Pharmaceuticals, Inc.
- Target Recruit Count
- 23
- Registration Number
- NCT01357395
- Locations
- 🇵🇱
Wojewódzki Szpital Specjalistyczny, Radom, Mazowieckie, Poland
🇺🇸Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
🇺🇸Vanderbilt - Ingram Cancer Center, Nashville, Tennessee, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.